Dong-E-E-Jiao Co., Ltd. Class A
SSZSE:00042346.96
CNY
+0.02
(+0.04%)
ISIN
CNE0000006Y9
Return %
Stock
S&P 500
1Y
-3.10
13.14
3Y
4.54
80.78
5Y
8.33
67.74
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Quarterly Revenue
CNY
•
in mil. unless spec.Quarterly Earnings Per Share
CNY
•
in mil. unless spec.Quarterly Dividends Per Share
CNY
•
in mil. unless spec.Company Description
- CEO
- Jinni Sun
- Full Time Employees
- 4,345
- Sector
- Health technology
- Industry
- Pharmaceuticals: other
- Address
- 78 Ejiao Street Liaocheng SD China 252201
- IPO Date
- Jul 29, 1996
- Website
- dongeejiao.com
- Similar Companies
- Business
- Dong-E-E-Jiao Co., Ltd. (000423.SZ) is a China-based company principally engaged in the research, development, production and sales of donkey-hide gelatin (Ejiao) and related traditional Chinese medicines; headquartered in Liaocheng, Shandong Province, and founded in 1952, it operates as a subsidiary of China Resources Pharmaceutical Group Limited, which holds an effective controlling stake of approximately 23.5%; the company manufactures and markets a comprehensive portfolio of over 100 products across six major categories, including Ejiao in forms such as blocks, Compound Ejiao Paste, Peach Blossom Princess Ejiao Cake, Ejiao instant powder, Royal Paddock 1619, Zhuangben Ejiao minced meat puree and Yan Zhenqing Ejiao bird's nest; additional offerings encompass Chinese patent medicines, health foods, foods, bio-medicines, pharmaceutic adjuvants and medical equipment, with the Dong-E branded Ejiao accounting for about 75% of national production and 90% of exports; products target domestic markets in eastern, southern, southwestern and northern China, as well as international customers in Southeast Asia, Europe and the United States. The company maintains advanced facilities including a national Ejiao traditional Chinese medicine engineering technology research center and a postdoctoral workstation, supporting over 300 patents and participation in national standards formulation; it employs around 4,000 staff and focuses on high-tech innovation as a national innovative enterprise. Recent developments include the launch in late 2024 of three desert ginseng (Cistanche deserticola) products under the Zhuangben brand—a concentrate, a tonic drink blended with donkey-hide gelatin, and a prebiotic paste—marking expansion into men's health, anti-aging and foods-as-medicines segments via a new subsidiary in Inner Mongolia's Alxa League; in 2025, the company revised its restricted stock incentive plan, adjusting the assessment period to 2025-2027 with elevated performance targets such as return on equity of at least 11.5-12.5%; it also deepened strategic partnerships, including with Shandong Sports Bureau, Shandong Radio and Television Station and Tencent Video for sports and health initiatives, and earned recognitions like 2025 Phoenix Star Most Socially Responsible Listed Company and a spot on the BrandZ Most Valuable Chinese Brands ranking; further, plans advance to acquire 80% of Inner Mongolia Alxa Cistanche Group and 70% of Dongfeng Majie Pharmaceutical to bolster supplement projects, while H1 2025 net profit rose 10.7-11% year-over-year amid ongoing R&D investments.